Replies to post #277839 on Avid Bioservices Inc (CDMO)

[goodJohnhunting]

Pfizer PFE.N, in a conference call with industry analysts:
• Says bococizumab at 52 weeks showed waning potency against LDL cholesterol in substantial number of patients
• Says disappointing trend at 52 weeks for bococizumab contrasted with robust efficacy seen at 12 weeks and 24 weeks
• Says waning efficacy of bococizumab likely was caused by neutralizing impact of naturally occuring antibodies
• Pfizer CEO says company aims to increase its involvement with cardiovascular drugs, including through acquisitions
• Pfizer CEO says remains interested in acquisitions, with no limit on size of potential deals
• Pfizer research chief says company aims to become a leader in combination therapies involving immuno-oncology drugs

This is close to saying "statin + immunotherapy"..

Why not use their current statin drug ATORVASTATIN + BAVITUXIMAB??

All the best,
John